论文部分内容阅读
Juno公司近日宣布已经收购了美国生物医药公司Redox Therapies,以获得其小分子药物vipadenant作为CAR-T疗法联合治疗成分。按照协议,Juno向后者支付了1000万美元的现金预付款,同时还承诺了数额不明的研发及商业化里程碑奖金。近段时间,Juno公司因为其临床实验中患者死亡问题被推上了风口浪尖。这一研究让外界对CAR-T疗法的安全性产生了不小的质疑。令Juno公司庆幸的是,尽管发生了这一不幸事件,FDA经过
Juno recently announced that it has acquired the U.S. biopharmaceutical company Redox Therapies to acquire its small molecule vipadenant as a combined treatment with CAR-T. Under the agreement, Juno paid the latter $ 10 million in cash advances and promised an unknown amount of research and development and commercial milestone bonuses. Recently Juno was pushed to the cusp because of the death of its patients in clinical trials. This study made the outside world on the safety of CAR-T therapy has produced no small challenge. Juno company is fortunate that, despite this unfortunate incident, FDA passed